RNAi Therapeutics

Arrowhead Pharmaceuticals successfully raised $625 million through convertible notes and common stock offerings. This substantial capital infusion will fund pipeline development, operations, and potential product launches. The offerings include 0.00% convertible senior notes due 2032 and common stock, with underwriters having options to purchase additional securities. The company also utilized capped call transactions to mitigate potential dilution from note conversions. Proceeds will support R&D, clinical trials, and general corporate purposes.

Alnylam Pharmaceuticals’ AMVUTTRA (vutrisiran) showed sustained benefits in transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) patients in the HELIOS-B Phase 3 study. Data presented at ESC Congress 2025 revealed that vutrisiran reduced the risk of all-cause mortality or first cardiovascular event by 37% in the overall population and 42% in the monotherapy group over 48 months. The open-label extension maintained improvements in quality of life and cardiac biomarkers, supporting vutrisiran as a potential first-line ATTR-CM therapy.